Document 0921
 DOCN  M9470921
 TI    Clinical aspects of the interactions between human immunodeficiency
       virus and the hepatotropic viruses.
 DT    9409
 AU    Horvath J; Raffanti SP; Division of Infectious Diseases, Vanderbilt
       University School of; Medicine, Nashville, Tennessee 37232-2605.
 SO    Clin Infect Dis. 1994 Mar;18(3):339-47. Unique Identifier : AIDSLINE
       MED/94281412
 AB    The hepatitis viruses A through D are prevalent among patients at risk
       for human immunodeficiency virus (HIV) infection. The courses of
       hepatitis B, C, and D are modified by HIV infection. With hepatitis B,
       increased carriage rates, increased viral replication, and milder liver
       injury are seen. The degree of HIV-induced immunosuppression does not
       correlate well with liver injury or amount of hepatitis B viral
       replication. With progression to AIDS, surface antibody titers can
       decline, resulting in reactivation of latent hepatitis B virus or
       reinfection with another subtype. hepatitis B virus may enhance
       progression to AIDS. Preliminary data suggest that HIV infection can
       prolong or increase hepatitis C or D viremia and decrease the accuracy
       of tests for hepatitis C. Interferon may have efficacy against hepatitis
       C but rarely against hepatitis B in patients who are coinfected with
       HIV. Zidovudine, ganciclovir, and foscarnet also may be active against
       these hepatotropic viruses.
 DE    Acquired Immunodeficiency Syndrome/ETIOLOGY  Antiviral
       Agents/THERAPEUTIC USE  Delta Infection/COMPLICATIONS  Hepatitis
       B/COMPLICATIONS  Hepatitis C/COMPLICATIONS  Hepatitis, Chronic
       Active/COMPLICATIONS  Hepatitis, Viral, Human/*COMPLICATIONS/THERAPY
       Human  HIV Infections/*COMPLICATIONS  Interferon-alpha/THERAPEUTIC USE
       JOURNAL ARTICLE  REVIEW  REVIEW, ACADEMIC

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).